A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

As the markets for weight-loss drugs develop, pharma companies are having to adapt in search of the next big thing.

Hims & Hers Health, a telehealth company, offers direct-to-patient platform to distribute prescription drugs and OTC ...

Hims & Hers Health stock plunged after Novo Nordisk (NYSE: NVO) cut ties over concerns about its handling of Wegovy ...

Top Alternatives to Ozempic That Are EffectiveReviewed by Dr. Craig Primack, MD, FACP, FAAP, FOMAOzempic is a medication ...

New data from GoodRx Research reveals just how inadequate and restrictive prescription insurance has become. Medicaid, often ...

Pharmaceutical giant Eli Lilly announced a price cut for its drug, Zepbound, for people who aren't using insurance. CBS News' Nancy Chen reports on the qualifications for the discount and what the ...

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing next-generation offerings.

Continuing high prices and demand for GLP-1 weight-loss drugs is creating lots of questions about the affordability of these drugs for U.S. healthcare consumers. For more than two years, drugs ...

Continuing high prices and demand for GLP-1 weight-loss drugs is creating lots of questions about the affordability of these drugs for U.S. healthcare consumers. For more than two years, drugs ...

The price of weight loss drugs is falling. Wegovy and Zepbound, which both sell for a list price of more than $1,000 a month , have long been out of reach for people without insurance or whose ...